Tara Lynn Kieffer sold $30k of ENTA
Chief Product Strategy Officer at ENANTA PHARMACEUTICALS INC. 2,106 shares at an average of $14.23, traded Dec 5, 2025, filed Dec 5, 2025.
Score components
- +15RoleOfficer
- +5Trade size$30k at market
- 0Share of holdings soldSold 6.4% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002064832-25-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | SOpen-market sale Common Stock | -2,106 | $14.23 | $30k | 30,620 | Dec 5, 2025 |
Related signals
Other insiders at ENANTA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | ENANTA PHARMACEUTICALS INC | Kathleen S. Capps See Remarks | $4,596 323 shares | -4% | |
| 48Moderate | ENANTA PHARMACEUTICALS INC | Jay R. Luly President and CEO | $67k 4,743 shares | -1% | |
| 36Weak | ENANTA PHARMACEUTICALS INC | Yat Sun Or Chief Scientific Officer | $34k 2,390 shares | -1% | |
| 30Weak | ENANTA PHARMACEUTICALS INC | Brendan Luu Chief Business Officer | $20k 1,394 shares | -4% | |
| 30Weak | ENANTA PHARMACEUTICALS INC | Scott T. Rottinghaus Chief Medical Officer | $11k 798 shares | -4% | |
| 30Weak | ENANTA PHARMACEUTICALS INC | Harry R. Trout III See Remarks | $7,713 542 shares | -3% | |
| 30Weak | ENANTA PHARMACEUTICALS INC | Kathleen S. Capps See Remarks | $2,890 207 shares | -2% | |
| 30Weak | ENANTA PHARMACEUTICALS INC | Harry R. Trout III See Remarks | $5,305 380 shares | -2% | |
| 41Moderate | ENTAbuy ENANTA PHARMACEUTICALS INC | Jay R. Luly President and CEO | $256k 45,000 shares | +6% | |
| 26Weak | ENANTA PHARMACEUTICALS INC | Jay R. Luly President and CEO | $41k 5,142 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.